EFFECTS of HALOPERIDOL, BROMOCRIPTINE and AMPHETAMINE ON the DEVELOPMENT of EHRLICH ASCITES-CARCINOMA in MICE

dc.contributorSCH MED MARILIA
dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorFrussa, R.
dc.creatorMonteiro, M. D.
dc.creatorSoares, CGS
dc.creatorDecio, R. C.
dc.date.accessioned2016-01-24T11:40:08Z
dc.date.accessioned2022-10-07T20:38:15Z
dc.date.available2016-01-24T11:40:08Z
dc.date.available2022-10-07T20:38:15Z
dc.date.created2016-01-24T11:40:08Z
dc.date.issued1992-07-01
dc.identifierPharmacology. Basel: Karger, v. 45, n. 1, p. 58-60, 1992.
dc.identifier0031-7012
dc.identifierhttp://repositorio.unifesp.br/handle/11600/25265
dc.identifier10.1159/000138973
dc.identifierWOS:A1992JG42500008
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4020407
dc.description.abstractWe determined the effect of 13 days of treatment with 2.0 mg/kg haloperidol, 4.0 mg/kg bromocriptine or 2.0 mg/kg amphetamine on the number of tumor cells of mice bearing Ehrlich ascites carcinoma. the dopaminergic blocker significantly reduced the number of tumor cells of experimental mice, but the two dopamine-mimetic drugs used did not significantly affect tumor development. These results suggest that although neuroleptic drugs do inhibit Ehrlich ascites tumors, this effect does not seem to be related to changes in dopaminergic neuronal transmission.
dc.languageeng
dc.publisherKarger
dc.relationPharmacology
dc.rightshttp://www.karger.com/Services/RightsPermissions
dc.rightsAcesso restrito
dc.subjectHALOPERIDOL
dc.subjectBROMOCRIPTINE
dc.subjectAMPHETAMINE
dc.subjectEHRLICH ASCITES CARCINOMA
dc.titleEFFECTS of HALOPERIDOL, BROMOCRIPTINE and AMPHETAMINE ON the DEVELOPMENT of EHRLICH ASCITES-CARCINOMA in MICE
dc.typeArtigo


Este ítem pertenece a la siguiente institución